Agent and composition for improving intrauterine flora, and method for determining whether intrauterine flora is improved or normalized
Lactoferrin-based compositions normalize the uterine bacterial flora by enhancing Lactobacillus occupancy, addressing infertility and reproductive issues through safe and effective methods.
Patent Information
- Application Number
- JP2020190524
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-09-20
- Filing Date
- 2020-11-16
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2039-09-11
AI Technical Summary
Conventional treatments for improving the intrauterine bacterial flora, such as vaginal irrigation and antibiotic administration, are ineffective and can have side effects, while there is a lack of methods to normalize the uterine flora, which is associated with infertility, miscarriage, and other reproductive issues.
A composition containing lactoferrin or its salt is used to improve the uterine bacterial flora, accompanied by a method to determine normalization through 16S ribosomal RNA gene amplification and microbiota analysis.
Lactoferrin effectively normalizes the uterine bacterial flora, enhancing Lactobacillus occupancy, thereby addressing infertility and other reproductive issues with minimal side effects and ease of administration.
Abstract
Description
[Technical field]
[0001] The present invention relates to an agent for improving intrauterine bacterial flora, a composition for improving intrauterine bacterial flora, and a method for determining whether intrauterine bacterial flora is in an improved or normalized state. [Background technology]
[0002] It was known that Lactobacillus bacteria are abundant in the vagina of healthy women of reproductive age, and that the lactic acid and antibacterial substances produced by Lactobacillus create an environment in which other pathogenic bacteria and viruses cannot grow, thereby playing a role in protecting the vagina from infection.
[0003] On the other hand, the bacterial environment in the uterus, although spatially connected to the vagina, has been considered to be sterile due to the presence of a mucosal barrier secreted from the cervix (Non-Patent Document 1). In the early 2000s, a DNA amplification method for the 16S ribosomal RNA (rRNA) gene characteristic of individual bacteria was established, making it possible to identify bacteria using the DNA sequence information of isolated bacteria. Furthermore, next-generation sequencing technology capable of analyzing huge amounts of DNA at once has appeared, making it possible to examine the presence of difficult-to-culture or trace amounts of bacteria without isolating them by analyzing the 16S rRNA genes derived from all the bacteria present in a sample at once. A bacterial community that is complexly composed of multiple bacteria is called a bacterial flora, microbiota, or flora, and it has become possible to understand what proportion of each bacterium accounts for in the whole. In recent years, bacterial flora analysis using this next-generation sequencer has revealed that bacterial flora also exists in the uterus. In 2015, Franasiak et al. of Rutgers University in the United States used a next-generation sequencer to investigate the intrauterine bacterial environment during in vitro fertilization and reported that many Lactobacillus bacteria live in the uterus (Non-Patent Document 2). In the same year, Mitchell et al. of the University of Washington also reported that the uterus also contains bacterial flora derived from the vagina, and that many Lactobacillus bacteria live in the normal endometrium (Non-Patent Document 3).
[0004] The bacterial environment in the reproductive tract is important in reproductive medicine, and it has been reported that it is related to infertility and repeated miscarriage, premature birth, or stillbirth. In particular, the intrauterine microbiota is very important for understanding the environment in the uterus to which the fertilized eggs are returned after IVF. In 2016, Moreno et al. from Spain investigated the relationship between infertility and the vaginal and uterine microbiota. As a result, they reported that the intrauterine microbiota is kept very stable during the implantation period, and that a decrease in Lactobacillus bacteria correlates with a decrease in the pregnancy rate, continued pregnancy rate, and successful birth rate of IVF patients (Non-Patent Document 4). Similarly, in 2017, Jia et al. from China investigated the bacterial flora of the female reproductive tract and reported that a unique bacterial flora is established in the reproductive tract from the vagina to the fallopian tubes. Bacteria in the vagina and uterus have been shown to correlate with reproductive diseases accompanied by infertility, and it has been suggested that they may be used as biomarkers for diseases in the future (Non-Patent Document 5).
[0005] The present inventors established a unique sampling method and analysis method to detect the intrauterine bacterial flora, which has a bacterial abundance of 1,000 to 10,000 times less than that of the vagina (Non-Patent Document 6). Using these methods, the intrauterine and vaginal bacterial flora of 7 healthy volunteers, 79 patients who underwent in vitro fertilization, and 23 general infertility patients were examined, and a discrepancy between the vaginal bacterial flora and the intrauterine bacterial flora was observed in about 30% of the total subjects. In addition, the intrauterine Lactobacillus occupancy rate was an average of 99.50% in healthy volunteers, while it was an average of 63.90% in patients who underwent in vitro fertilization. Furthermore, the Lactobacillus occupancy rate of 18 people who became pregnant during the study period was 96.45%, revealing that the pregnancy group had a higher intrauterine Lactobacillus occupancy rate.
[0006] As described above, new analytical techniques have revealed that the bacterial flora in the uterus is different from that in the vagina. To date, it has been pointed out that the intrauterine bacterial flora is related to endometriosis, endometrial cancer, endometritis, and chorioamnionitis, as well as pregnancy outcomes (Non-Patent Document 1). Infection of the cervix is called cervicitis. On the other hand, inflammation of the uterine body is called endometritis for inflammation of the endometrium, myometritis for inflammation of the muscle layer, and perimetritis for inflammation of the serosal membrane, depending on the affected lesion, but most cases are endometritis. Most endometritis is an ascending infection, and examples of causative bacteria include streptococci, staphylococci, Escherichia coli, and anaerobic bacteria. If these bacteria infect the chorion or amniotic fluid during pregnancy, it will cause chorioamnionitis, which will lead to premature birth. Since such infections are thought to be caused by mild disturbance of the intrauterine bacterial flora, it is important to improve the intrauterine bacterial flora.
[0007] However, conventional treatments such as vaginal washing, antibiotic administration, and hormone therapy are not effective enough to improve the intrauterine environment. Penicillin-based antibiotics such as ampicillin and amoxicillin are not effective against anaerobic bacteria, and are not recommended as a treatment for bacterial vaginosis in the JAID / JSC Infectious Disease Treatment Guidelines 2014 and Sanford. Therefore, these antibiotics alone are thought to be less effective in increasing Lactobacillus. It is also known that side effects of antibiotic treatment can rarely cause damage to the skin, liver, etc.
[0008] Thus, there is an increasing need to develop a treatment that can normalize the disturbance of the intrauterine bacterial flora; however, to date, there have been no reports of therapeutic or interventional methods to improve the intrauterine bacterial flora.
[0009] Lactoferrin is an iron-binding protein discovered in cow's milk in 1939, and has since been found to be present in the milk of many mammals other than cows. Lactoferrin is found in large amounts in human breast milk, especially colostrum, but is also found in tears, saliva, pancreatic juice and other exocrine fluids and neutrophils in adults. Lactoferrin has bacteriostatic activity due to its ability to deprive bacteria of the iron necessary for their survival and proliferation, and also has antibacterial activity, such as bacterial lysis via binding to lipopolysaccharides in the bacterial membrane, inhibition of bacterial adhesion to epithelial cells, and inhibition of invasion into host cells (Non-Patent Document 7).
[0010] In 2012, Giunta et al. reported that when 200 mg of lactoferrin was orally administered per day to iron-deficient pregnant women for one month, vaginal infections were cured, the vaginal microbial flora was normalized, and the risk of premature birth was reduced (Non-Patent Document 8). Similarly, in 2014, Otsuki et al. reported that lactoferrin, a protein component derived from milk, is effective in preventing premature birth (Non-Patent Document 9). According to a paper by Otsuki et al. in 2017, the vaginal bacterial flora of women with refractory bacterial vaginosis who repeatedly gave birth prematurely was significantly reduced in Lactobacillus bacteria, a type of lactic acid bacteria that is abundant in normal vaginas, and that by administering lactoferrin orally (700 mg / day) and directly into the vagina for a long period of time, the Lactobacillus bacteria increased, leading to pregnancy and subsequent delivery without premature birth (Non-Patent Document 10). In 2017, Pino et al. in Italy reported that when 100-200 mg of lactoferrin was administered intravaginally to patients with bacterial vaginosis and bacteria were examined two weeks later, Gardnerella, Prevotella, and Lachnospira were significantly decreased, while Lactobacillus was increased (Non-Patent Document 11). From the above, lactoferrin has been recognized to have a prebiotic effect that shows a proliferation effect on Lactobacillus in the vagina, and lactoferrin has been shown to be effective in treating bacterial vaginosis.
[0011] As such, the effect of lactoferrin, a physiologically active protein, in improving the vaginal bacterial flora has been reported in recent years, but its effect on the uterine bacterial flora is still unknown. [Prior art documents] [Non-patent literature]
[0012] [Non-Patent Document 1] Baker JM et al., Front Immunol. 2018 Mar 2;9:208. Uterine Microbiota: Residents, tourists, or invaders? [Non-Patent Document 2] Franasiak JM et al., J Assist Reprod Genet. 2016 Jan;33(1):129-36. Endometrial microbiome at the time of embryo transfer: next-generation sequencing of the 16S ribosomal subunit. [Non-Patent Document 3] Mitchell CM et al., Am J Obstet Gynecol. 2015 May;212(5):611.e1-9. Colonization of the upper genital tract by vaginal bacterial species in nonpregnant women. [Non-Patent Document 4] Moreno I et al., Am J Obstet Gynecol. 2016 Dec;215(6):684-703. Evidence that the endometrial microbiota has an effect on implantation success or failure. [Non-Patent Document 5] Chen C et al., Nat Commun. 2017 Oct 17;8(1):875. The microbiota continuum along the female reproductive tract and its relationship to uterine-related diseases.
Outdoor Configuration6
Direct Environment 7
Outdoor Track 8
Outdoor Tools9
Outdoor Tools 10
[0013] The present invention aims to provide an agent and composition for improving the intrauterine bacterial flora. Another aim of the present invention is to provide a method for determining the improvement or normalization of the intrauterine bacterial flora. [Means for solving the problem]
[0014] The present inventors discovered that lactoferrin improves the intrauterine bacterial flora, and thus completed the present invention. According to the present invention, [1] An agent for improving intrauterine bacterial flora, which contains lactoferrin or a salt thereof as an active ingredient; [2] A therapeutic or preventive agent for diseases caused by disturbance of intrauterine bacterial flora, such as infertility, miscarriage, premature birth, infertility, endometriosis, endometrial cancer, cervicitis, endometritis, and / or chorioamnionitis, which contains lactoferrin or a salt thereof as an active ingredient; [3] A composition containing the agent according to [1] or [2] above; [4] The composition according to [3] above, which is a pharmaceutical composition; [5] The composition according to [3] above, which is a food or drink composition; [6] A method for assessing an improved or normalized state of intrauterine bacterial flora, comprising the steps of: measuring the Lactobacillus occupancy rate in intrauterine bacterial flora by a bacterial flora analysis method based on amplification of the 16S ribosomal RNA gene using multiple samples collected from the uterus of a subject at two or more time points before, during, or after administration or ingestion of the agent or composition described in any one of [1] to [5] above; and calculating the difference in the occupancy rate between the multiple samples; [7] The method according to [6] above, wherein the bacterial flora analysis technique is an amplicon sequencing method that amplifies the 16S ribosomal V4 region; [8] a method for treating or preventing a disease caused by disturbance of intrauterine bacterial flora, comprising administering to a subject an agent for improving intrauterine bacterial flora, which contains lactoferrin or a salt thereof as an active ingredient, or a composition containing said agent; [9] the method according to [8] above, wherein the disease caused by disruption of intrauterine bacterial flora is one or more of infertility, miscarriage, premature birth, infertility, endometriosis, endometrial cancer, cervicitis, endometritis, and / or chorioamnionitis; is provided. Effect of the Invention
[0015] The present invention provides an effective means for normalizing intrauterine bacterial flora. Lactoferrin is a component contained in breast milk, and is very safe, with little risk of side effects, so it can be easily used in combination with other medicines. In addition, lactoferrin is also used as a component of food and supplements, and can be easily administered or ingested orally, so that intrauterine bacterial flora can be improved without the need for treatment at a medical institution. Therefore, the agent or composition of the present invention can safely and easily normalize intrauterine bacterial flora.
[0016] The method of the present invention for determining an improved or normalized state of the intrauterine bacterial flora allows the effect of the agent or composition of the present invention to be determined easily, and makes it easy to determine whether or not to continue administering or taking the agent or composition of the present invention, as well as whether or not to add or change other treatments. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0017] The agent of the present invention contains lactoferrin or its salt as an active ingredient.The composition of the present invention, such as a pharmaceutical composition or a food and drink composition, is a composition containing the agent of the present invention containing lactoferrin as an active ingredient.The agent or composition of the present invention, such as a pharmaceutical composition or a food and drink composition, is effective for improving intrauterine flora.In the present invention, the improvement of intrauterine flora refers to increasing the occupancy rate of Lactobacillus in intrauterine flora.The method for determining the improvement or normalization of intrauterine flora will be described later.
[0018] Lactoferrin is a polymer with a molecular weight of about 80,000 and has the property of forming a chelate with two trivalent iron ions, but the "lactoferrin" used in the present invention is not limited to lactoferrin derived from living organisms extracted from mammalian milk, etc., and any lactoferrin may be used as long as it exhibits the biological activity of lactoferrin, especially the effect of improving the endometrial flora. Examples include natural lactoferrin (for example, bovine lactoferrin contained in bovine milk) obtained from various mammals including humans (for example, cows, horses, pigs, sheep, goats, camels, etc.), apolactoferrin (iron ion free type) obtained by removing iron from lactoferrin by a conventional method, metal-saturated or non-saturated lactoferrin obtained by chelating apolactoferrin with metal ions (iron, copper, zinc, manganese, etc.), genetically engineered recombinant lactoferrin produced by genetic engineering technology, and lactoferrins bound to polyethylene glycol chains. In addition, recombinant lactoferrin includes not only recombinant lactoferrin produced based on a modified lactoferrin gene, but also lactoferrin secreted by transgenic animals and functional equivalents such as active fragments of lactoferrin.
[0019] The salts of lactoferrin that can be used in the present invention are any physiologically acceptable salts of lactoferrin as described above, such as sodium salts, potassium salts, sulfate salts, phosphate salts, and the like.
[0020] The agent or composition of the present invention may contain only one type of lactoferrin as described above, or may contain two or more types. Since lactoferrin is a known substance, commercially available products can be used. Also, lactoferrin purified from milk or the like containing lactoferrin by a known method, for example, a method of purifying lactoferrin using a sulfonated carrier (JP Patent Publication No. 3-109400), can be used. Furthermore, depending on the application, fractions from milk or the like that contain lactoferrin at a high concentration (for example, fractions obtained by removing sugars from milk) can also be used.
[0021] The agent of the present invention has lactoferrin as the only essential component, but the agent or composition of the present invention may contain various components or additives known in the pharmaceutical or food industry as desired. The form of the pharmaceutical composition or food and drink composition of the present invention is not particularly limited. The food and drink composition of the present invention is orally administered, and may be in the form of various foods, food ingredients, beverages, drinks, etc. The composition of the present invention is preferably in the form of a convenient dosage form for oral administration, such as a powder, powder, granules, tablets, or capsules.
[0022] Examples of additives that may be contained in the compositions such as the pharmaceutical composition and food and beverage composition of the present invention include excipients, disintegrants, lubricants, binders, surfactants, flow enhancers, colorants, flavors, etc. that are routinely used in the pharmaceutical or food industry. These additives are appropriately selected depending on the desired dosage form, etc.
[0023] For example, when the pharmaceutical composition or food and drink composition of the present invention is in the form of a powder, granule, tablet, capsule, etc., the excipients used include monosaccharides or disaccharides such as lactose, sucrose, glucose, sorbitol, lactitol, etc., starches such as corn starch and potato starch, crystalline cellulose, and inorganic substances such as light silica gel, synthetic aluminum silicate, magnesium aluminometasilicate, calcium hydrogen phosphate, silicon dioxide, etc. In addition to the excipients, binders, disintegrants, surfactants, lubricants, flow enhancers, colorants, flavors, etc. can be used as necessary.
[0024] Disintegrants include starches, carboxymethylcellulose (CMC), hydroxypropylcellulose (HPC), carboxymethylcellulose sodium salt, polyvinylpyrrolidone, etc. Lubricants include sucrose fatty acid esters, calcium stearate, magnesium stearate, etc. Examples of binders include starch, dextrin, powdered gum arabic, gelatin, hydroxypropyl starch, sodium carboxymethylcellulose, methylcellulose, crystalline cellulose, ethylcellulose, and polyvinylpyrrolidone. Examples of surfactants include soybean lecithin and sucrose fatty acid esters. Examples of lubricants include talc, wax, sucrose fatty acid esters, hydrogenated vegetable oil, calcium stearate and magnesium stearate. Examples of flow enhancers include anhydrous silicic acid, dried aluminum hydroxide and magnesium silicate.
[0025] Since lactoferrin is unstable at high temperatures and humidity, the composition of the present invention is preferably formulated in a dry state.
[0026] Since lactoferrin powder usually cannot be tableted as it is due to its very low specific gravity, in order to obtain the composition of the present invention, which is a stable formulation that maintains its pharmacological effect, for example, the active ingredient is mixed with an excipient, a binder, and a disintegrant, and the mixture is pressed in a slug machine to form a thin, large, flat disk, which is then crushed and sieved to obtain granules of a certain size. When making tablets, it is preferable to add a lubricant to the granules and tablet them, and if necessary, cover the tablets with a coating film to produce the product. When making capsules, it is preferable to fill a certain amount of the granules into capsules to produce capsules.
[0027] The oral (pharmaceutical or food and beverage) composition of the present invention may be prepared as an enteric preparation. It is known that lactoferrin is decomposed by pepsin, a proteolytic enzyme in the stomach, under acidic gastric conditions, and the site of lactoferrin's absorption is believed to be present in the intestinal tract, mainly the small intestine. There is no particular limitation on the method of processing lactoferrin into an enteric preparation. For example, to prepare an enteric preparation, an enteric capsule may be prepared with a film mainly composed of a base material that is resistant to gastric juice and dissolves in the small intestine, such as a base material selected from the group consisting of shellac, hydroxypropylmethylcellulose phthalate, carboxymethylethylcellulose, cellulose acetate phthalate, methacrylic acid copolymer, water-insoluble ethylcellulose and aminoalkyl methacrylate copolymer, and filled with granules containing an active ingredient, or a lubricant may be added to granules containing an active ingredient, and the tablets obtained by tableting may be coated with the above-mentioned film.
[0028] Whether the manufactured composition is enteric or not can be confirmed by testing the disintegration using a first solution (pH 1.2, Japanese Pharmacopoeia, General Testing Method 41) made by dissolving 2.0 g of sodium chloride with hydrochloric acid and water to make 1000 ml, and a second solution (pH 6.8) made by adding 118 ml of 0.2 N sodium hydroxide solution and water to 250 ml of 0.2 M potassium dihydrogen phosphate solution to make 1000 ml. Tablets or granules that do not disintegrate when immersed in the first solution for 120 minutes but disintegrate when immersed in the second solution for 60 minutes do not dissolve in the stomach, but disintegrate only when they flow into the duodenum, and the active ingredient is dissolved, and can be determined to be enteric.
[0029] A method for delivering lactoferrin to the intestinal tract other than the use of enteric preparations is the use of liposome preparations consisting of a lipid bilayer. Liposome preparations also do not disintegrate in the stomach, but are emulsified and disintegrated by bile in the small intestine, so lactoferrin can be delivered to the absorption site in the intestinal tract. Alternatively, a method may be used in which the pH in the stomach is simply increased, i.e., an alkaline agent is used in combination, so that pepsin does not act on lactoferrin.
[0030] The route of administration of the agent or composition of the present invention is, for example, oral, transdermal, injection, enteral, rectal administration, etc. The preferred route of administration of the pharmaceutical composition and food and drink composition of the present invention is oral.
[0031] The agent or composition of the present invention may be administered alone or in combination with other drugs. When the agent or composition of the present invention is administered in combination with other drugs, the two may be used simultaneously or in sequence.
[0032] The daily administration or intake amount of the agent or composition of the present invention that is effective in improving the intrauterine bacterial flora will vary depending on the formulation, administration method, age and body weight of the subject, etc., but in humans, generally, about 0.1 mg to about 5,000 mg, preferably about 0.5 mg to about 2,000 mg, and most preferably about 10 mg to about 1,000 mg of lactoferrin as an active ingredient can be administered all at once or in divided doses before meals, after meals, between meals, and / or before bedtime, etc.
[0033] The agent or composition of the present invention can be administered to humans and non-human animals, preferably mammals. Examples of non-human animals include livestock such as cows, horses, pigs, and sheep, and companion animals such as dogs and cats. The amount of lactoferrin administered or ingested is preferably 0.2 mg to 300 mg / kg body weight / day in mammals such as pets (excluding humans).
[0034] Whether or not the intrauterine bacterial flora has been improved or normalized by the agent or composition of the present invention can be determined by measuring the Lactobacillus occupancy rate in the intrauterine bacterial flora using a bacterial flora analysis method based on amplification of the 16S rRNA gene using samples collected from the subject's uterus at two or more time points before, during, or after administration or ingestion of the agent or composition of the present invention, and comparing the occupancy rates of multiple samples collected at different time points and calculating the difference.
[0035] The specimen is a sample collected from inside the uterus that contains intrauterine bacteria, and the collection method is not limited, but for example, intrauterine fluid collected using a suction pipette can be used.
[0036] The combination of time points at which samples are collected is not particularly limited, and may be any time point before, during, or after administration or ingestion of the agent or composition of the present invention, as long as there is an interval of one day or more. Samples at two or more time points preferably include at least one sample during or after administration or ingestion of the agent or composition of the present invention. For example, when samples are collected at two time points, it is preferable that the samples are collected before, during, or after administration or ingestion of the agent or composition of the present invention; at two different time points during administration or ingestion; during and after administration or ingestion; or at two different time points after administration or ingestion.
[0037] The bacterial flora analysis method used in the determination method of the present invention generally includes the following steps: (1) extracting genomic DNA from a specimen collected from a subject and amplifying a portion or the entire DNA sequence of the bacterial 16S rRNA gene; (2) preparing a library in which an adapter sequence is added to the DNA amplification product, and sequencing the library using a next-generation sequencer; (3) combining the obtained sequence reads with data analysis software, the origin of the bacteria and its occupancy in the specimen are estimated.
[0038] Examples of bacterial flora analysis methods based on the amplification of 16S rRNA genes include 16S amplicon sequencing, shotgun sequencing, 16S full-length amplicon sequencing, and equivalent bacterial flora analysis methods. As the region to be amplified in the 16S rRNA gene, it is preferable to use the variable regions V1-V2, V3-V5, and / or V4, which are commonly used in 16S rRNA sequencing of human samples. In particular, it is preferable to use a primer set targeting the V4 region, which can detect bacteria present in the reproductive organs with high sensitivity, and the amplicon sequencing method targeting the V4 region is most preferable because it can detect a wide range of microorganisms including Pseudomonas, Escherichia, Salmonella, Lactobacillus, Enterococcus, Listeria, Bacillus, Gardnerella, Bifidobacterium, and two types of yeast.
[0039] In the present invention, the state of normalization of intrauterine bacterial flora refers to the state in which the Lactobacillus occupancy rate is 50% or more when the specimen taken from the uterus is measured by the bacterial flora analysis method based on the amplification of 16S rRNA gene as described above, and this Lactobacillus occupancy rate is preferably 70% or more, more preferably 90% or more.When the difference in the measured values of the same specimen by various methods exceeds the general error range, the value measured by the bacterial flora analysis method by the 16S amplicon sequence method using next-generation sequencer (for example, product name "MiSeq" (Illumina KK)) is used as the standard.
[0040] In the present invention, an improved state of intrauterine bacterial flora refers to, when samples taken from the uterus at two time points are measured using the bacterial flora analysis method described above, an increased Lactobacillus occupancy rate is observed in the later sample compared to the earlier sample. EXAMPLES
[0041] The present invention will be described in more detail below with reference to examples.
[0042] [Example 1] The inventors conducted an analysis of the intrauterine bacterial flora in patients aged 45 years or younger undergoing in vitro fertilization who visited an infertility clinic, and orally administered lactoferrin to patients (subjects) who were found to have an imbalance in the intrauterine bacteria, and examined the effects of this treatment.
[0043] <Uterine flora analysis> The intrauterine bacterial flora analysis was carried out basically according to the method described in Non-Patent Document 6 as follows. The mucus of the subject's cervix and cervix was wiped, and an embryo transfer catheter (trade name "Kitazato (registered trademark) IUI catheter" (Kitazato Corporation, Japan)) was carefully inserted from the vagina into the uterus, and intrauterine fluid was collected as a sample. The collected intrauterine fluid was transferred to 1 mL of a preservation solution (trade name "MMB collection tube" (DNA Genotek Inc., Canada)) for inactivating and stabilizing bacteria.
[0044] To extract the bacterial genomic DNA, proteinase K and lysozyme were added to the preservation solution to dissolve the bacteria. Genomic DNA was extracted using a DNA extraction kit (product name "Agencourt Genfind v2 Blood & Serum DNA Isolation Kit" (Beckman Coulter Inc, USA)). The concentration of the extracted DNA was measured using the product name "Qubit dsDNA HS Assay Kit" (ThermoFisher Scientific KK).
[0045] The bacterial flora analysis was carried out by the 16S amplicon sequencing method using a next-generation sequencer. Based on the protocol of the "Earth Microbiome Project" (Non-Patent Document 12), the bacterial DNA was amplified using a primer that linked a sequence that amplifies the V4 region of the 16S rRNA gene and an Illumina Nextera XT adapter sequence (Non-Patent Document 6). For PCR, a mixture of 25 ng / μL DNA, 200 μmol / L of each deoxyribonucleotide triphosphate, 400 nmol / L of each primer, 2.5 U of "FastStart HiFi polymerase", 20 mg / mL BSA (Sigma), and a buffer (Roche) containing 0.5 mol / L betaine (Sigma) and MgCl2 was prepared. PCR was performed using a thermal cycler (product name "SimpliAmp Thermal Cycler" (Thermo Fisher)), and after denaturation at 94 ° C for 2 minutes, 30 cycles of 94 ° C for 20 seconds, 50 ° C for 30 seconds, 72 ° C for 1 minute were performed, and finally, the reaction was performed at 72 ° C for 5 minutes. The PCR product was purified with the product name "Agencourt AMPure XP" (Beckman Coulter Inc, USA). Next, a library was prepared using the product name "Nextera XT Index kit" (Illumina Inc., USA) based on the "Illumina 16S Metagenomic Sequencing Library Preparation protocol" (https: / / support.illumina.com / documents / documentation / chemistry_documentation / 16s / 16s-metagenomic-library-prep-guide-15044223-b.pdf). The prepared library was sequenced by 2 × 200-bp paired-end sequencing using the product name "MiSeq Reagent Kit v3" (Illumina KK).Data analysis consisted of quality check of the entire sequence using “fastqQC” ( https: / / www.bioinformatics.babraham.ac.uk / projects / fastqc / ), and identification of fungi to the genus level was performed using “USEARCH” ( https: / / www.drive5.com / usearch / ) and “QIIME” ( http: / / qiime.org / ).
[0046] <Case 1> The subject was found to have a non-Lactobacillus dominant microbiota consisting of 40% Lactobacillus and 60% Streptococcus. The subject was administered 750 mg / day of the penicillin antibiotic amoxicillin for 7 days. After that, a commercially available lactoferrin preparation (trade name "Lactoferrin GX" (NRL Pharma)) was orally administered at a dose of 300 mg / day of lactoferrin. A second analysis of the intrauterine microbiota was performed after 50 days of continuous lactoferrin administration, and the Lactobacillus increased to 100%, indicating an improvement in the intrauterine microbiota.
[0047] Amoxicillin has a low effect on anaerobic bacteria, and amoxicillin alone has little effect on increasing Lactobacillus, so it is possible that Lactobacillus may have become a target of amoxicillin. Therefore, it is thought that administration of lactoferrin increased Lactobacillus in the uterus and improved the intrauterine bacterial flora.
[0048] <Case 2> This subject had an extremely unbalanced intrauterine flora, with the results of the first intrauterine flora analysis showing 0.1% Lactobacillus, 94.7% Streptococcus, and 5.2% others. The subject was administered 750 mg of amoxicillin / day for 14 days. From the fifth day after the start of amoxicillin administration (32 days after the first examination), the same lactoferrin preparation as in Case 1 was continuously orally administered at a lactoferrin dose of 300 mg / day. In the second intrauterine flora analysis performed after the end of amoxicillin administration (57 days after the first examination / 25 days after the start of lactoferrin administration), streptococcus had decreased to 17% and lactobacillus had increased to 16.2%, but there was a significant increase in other bacteria such as Escherichia. Since amoxicillin alone was not effective, the cephalosporin antibiotic cefdinir was administered at 300 mg / day for 7 days from the 53rd day after the start of lactoferrin administration (85 days after the first examination) in combination with a probiotic tampon (trade name "Florgynal Tampon Probiotique" (Laboratoires IPRAD, Paris, France)). After these treatments were completed, the lactoferrin preparation was continued alone, and as a result, in the third examination, which was performed 119 days after the first examination, the Lactobacillus had improved to 98.1%. The lactoferrin preparation was continued at a dose of 300 mg / day for 142 days. The subject subsequently became pregnant naturally.
[0049] Therefore, it was found that lactoferrin can improve the imbalance of intrauterine flora, and can prevent or improve various problems caused by the disturbance of intrauterine flora. In addition, no side effects were reported during the implementation of this test. Therefore, it can be said that this method and the lactoferrin preparation used are highly safe.
[0050] [Example 2] Preparation of lactoferrin tablets 20 kg of lactoferrin powder extracted from milk (protein purity 95% or more; lactoferrin in protein 90% or more) was mixed with 18.5 kg of lactose, 19.7 kg of crystalline cellulose (trade name "Avicel"), 1.2 kg of carboxymethylcellulose calcium salt, and 0.6 kg of sucrose fatty acid ester, and the resulting mixture was pulverized in a mixer to obtain a powder that passed through a 100 mesh. This mixed powder was compressed into tablets with a major axis of 9 mm and a weight of 300 mg. Each tablet contains 100 mg of lactoferrin powder.
[0051] [Example 3] Preparation of enteric-coated lactoferrin tablets (part 1) The tablets produced in Example 2 were placed in a coating machine (HiCoater HCT-48N, manufactured by Freund Corporation). An enteric coating solution consisting of 9.6% by mass of shellac, 1.5% by mass of L-arginine, 1.9% by mass of sorbitol, 2.4% by mass of sucrose fatty acid ester, 4.8% by mass of ethanol, and 79.8% by mass of purified water was sprayed onto the tablets, providing an enteric coating of 8 to 9% by mass relative to the tablets to produce a product.
[0052] [Example 4] Preparation of enteric-coated lactoferrin tablets (part 2) The tablets produced in Example 2 were placed in a coating machine (HiCoater HCT-48N, manufactured by Freund Corporation). An enteric coating liquid consisting of 9% by mass of carboxymethylcellulose, 1% by mass of glycerin fatty acid ester, 45% by mass of ethanol, and 45% by mass of methylene chloride was sprayed onto the tablets to provide an enteric coating of 12% by mass relative to the tablets, thereby producing a product.
[0053] [Example 5] Preparation of enteric-coated lactoferrin tablets (part 3) The tablets produced in Example 2 were placed in a coating machine (HiCoater HCT-48N, manufactured by Freund Corporation). An enteric coating solution prepared by dissolving 8 parts by mass of zein, a protein obtained from corn kernels, and 2 parts by mass of glycerin in 150 parts by mass of a 70% by mass aqueous ethanol solution was sprayed onto the tablets to obtain tablets coated with a coating of 10% by mass relative to the tablets.
[0054] [Example 6] Preparation of enteric-coated lactoferrin tablets (part 4) The tablets produced in Example 2 were placed in a coating machine (HiCoater HCT-48N, manufactured by Freund Corporation). An enteric coating solution prepared by dissolving 30 parts by mass of shellac and 7 parts by mass of castor oil in 63 parts by mass of isopropanol was sprayed onto the tablets to obtain tablets coated with a coating of 10% by mass relative to the tablet.
[0055] This application is based on a Japanese patent application, Patent Application No. 2018-176473, filed on September 20, 2018, and the contents of the specification and claims of Patent Application No. 2018-176473 are incorporated herein by reference.
Claims
1. An agent for improving intrauterine bacterial flora, which contains lactoferrin or a salt thereof as an active ingredient, and which normalizes the Lactobacillus occupancy rate in non-Lactobacillus-dominated intrauterine bacterial flora, where the Lactobacillus occupancy rate is less than 50%, to 70% or more.
2. The agent according to claim 1, which normalizes the Lactobacillus occupancy rate in the intrauterine bacterial flora to 90% or more.
3. The agent according to any one of claims 1 to 2, for treating or preventing a disease caused by disturbance of intrauterine bacterial flora, selected from infertility, miscarriage, premature birth, and / or recurrent pregnancy loss.
4. The agent according to any one of claims 1 to 2 for treating or preventing infertility.
5. The agent according to any one of claims 1 to 2, which is an agent for oral administration.
6. A composition for improving the intrauterine bacterial flora, comprising an agent according to any one of claims 1 to 5, which normalizes the Lactobacillus occupancy rate in a non-Lactobacillus-dominated intrauterine bacterial flora in which the Lactobacillus occupancy rate is less than 50% to 70% or more.
7. The composition of claim 6 which is a pharmaceutical composition.
8. The composition according to claim 6, which is a food or drink composition.
Citation Information
Patent Citations
JPP6831548B
